TARGETED THERAPY

Prolanta is a variant of normal human hormone prolactin (PRL) in which the single glycine amino acid at position 129 has been substituted with arginine. With this modification of the PRL molecule, Prolanta blocks PRL's action by preventing it from binding to the PRL receptor (PRLR).

PRL is a peptide hormone associated with mammary gland development and lactation and development of the ovaries. PRL is synthesized and secreted mainly by lactotroph cells in the anterior pituitary gland. When PRL binds to the PRLR, it causes it to dimerize with another receptor and activate the JAK-STAT intracellular pathway. This pathway plays a central role in cell fate decisions, such as cell proliferation, differentiation and apoptosis (programmed cell death).

Monotherapy

Combination Therapy